A Chinese patent for antiviral treatment was granted on September 15, 2026, covering compounds that inhibit V‑ATPase activity, according to the company's filing. The patent, numbered ZL 2021‑8‑0048053‑9, was filed on May 10, 2021, and lists four Indian inventors on the certificate.
The IPO, priced at ₹352 per share, was launched in October 2024 and drew a 1.83‑fold subscription, with the qualified institutional buyer segment at 2.76×. The issue raised ₹555 crore, comprising a fresh issuance of ₹325 crore and an offer‑for‑sale of 65.27 lakh shares.
Trading has since seen the shares settle at ₹246.74, a 13% rally from the last close but still trading 30% below the issue price. The 9% gain from the initial spike is holding as the market digests the patent news.
No forward guidance has been issued yet, but the patent could unlock new revenue streams in antiviral therapeutics. Analysts are monitoring the company’s future filing activity for clues on commercialization timelines.